Reimbursement Challenges and Solutions with Molecular Biomarker Testing

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.

Related Videos

January 20, 2016

Understanding How Cancer Stem Cells Grow

Dr Gerson discusses the process in which genetic changes cause tumors to grow.

July 25, 2018

New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?

Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes.